MCID: LYM129
MIFTS: 69

Lymphoma, Mucosa-Associated Lymphoid Type

Categories: Genetic diseases, Blood diseases, Rare diseases, Cancer diseases, Immune diseases, Gastrointestinal diseases

Aliases & Classifications for Lymphoma, Mucosa-Associated Lymphoid Type

MalaCards integrated aliases for Lymphoma, Mucosa-Associated Lymphoid Type:

Name: Lymphoma, Mucosa-Associated Lymphoid Type 57 75 38
Malt Lymphoma 57 38 12 59 75 55 15
Mucosa-Associated Lymphoid Tissue Lymphoma 12 59 73
Gastric Lymphoma, Primary 57 75 55
Lymphoma, Malt, Somatic 57 75 13
Extranodal Marginal Zone B-Cell Lymphoma 59 73
Marginal Zone B-Cell Lymphoma 75 73
Maltoma 59 75
Mucosa-Associated Lymphatic Tissue Lymphoma 59
Familial Primary Gastric Lymphoma 73
Lymphoma, B-Cell, Marginal Zone 44
Lymphoma, Gastric, Primary 40
Primary Gastric Lymphoma 75
Gastric Lymphoma 73

Characteristics:

Orphanet epidemiological data:

59
malt lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (United States),1-9/100000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



Summaries for Lymphoma, Mucosa-Associated Lymphoid Type

UniProtKB/Swiss-Prot : 75 Lymphoma, mucosa-associated lymphoid type: A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro- intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

MalaCards based summary : Lymphoma, Mucosa-Associated Lymphoid Type, also known as malt lymphoma, is related to follicular lymphoma and lymphoma. An important gene associated with Lymphoma, Mucosa-Associated Lymphoid Type is BCL10 (B Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Amoxicillin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are visual impairment and abnormality of the thyroid gland

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in mucosal tissue involved in antibody production.

OMIM : 57 The concept of mucosa-associated lymphoid tissue (MALT) lymphomas was introduced by Isaacson and Wright (1983). MALT lymphomas are now recognized as a distinct subtype of non-Hodgkin lymphoma (605027). B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) are the most common form of lymphoma arising in extranodal sites, in most cases arising in the gastric mucosa (Isaacson and Spencer, 1995). (137245)

Related Diseases for Lymphoma, Mucosa-Associated Lymphoid Type

Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 32.5 BCL10 BCL6 CCND1 CD40 IGH MME
2 lymphoma 32.1 BCL10 BCL6 CCND1 CXCR5 MALT1
3 primary cutaneous marginal zone b-cell lymphoma 31.0 BCL10 MALT1
4 marginal zone b-cell lymphoma 30.9 BCL10 BCL6 BIRC3 CD5 MALT1 MME
5 prostate lymphoma 30.8 BIRC3 CD5 MALT1
6 breast lymphoma 30.7 BCL6 CD5
7 diffuse large b-cell lymphoma 30.7 BCL10 BCL6 CARD11 CD5 FOXP1 MALT1
8 nodal marginal zone lymphoma 30.6 CD5 IGH
9 splenic marginal zone lymphoma 30.5 BCL6 BIRC3 CD5 MALT1
10 mantle cell lymphoma 30.0 BCL6 CCND1 CD40 CD5 IGH MALT1
11 b-cell lymphomas 30.0 BCL10 BCL6 BIRC3 CARD11 CCND1 CD40
12 peripheral t-cell lymphoma 29.9 BCL6 CD5 CXCL13 CXCR3 MME
13 nodal marginal zone b-cell lymphoma 10.9 BCL6 MALT1
14 follicular lymphoma 1 10.9 BCL10 BCL6 IGH
15 tracheal lymphoma 10.9 CD5 MME
16 orofaciodigital syndrome viii 10.9 BCL10 BIRC3 MALT1
17 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.8 BCL6 CXCR5
18 gallbladder lymphoma 10.8 BCL6 MME
19 heart lymphoma 10.8 BCL6 MME
20 nodular lymphocyte predominant hodgkin lymphoma 10.8 BCL6 CCND1
21 central nervous system lymphoma 10.8 BCL6 FOXP1 MALT1
22 testicular lymphoma 10.8 BCL6 FOXP1 MME
23 primary mediastinal large b-cell lymphoma 10.7 BCL6 FOXP1
24 intravascular large b-cell lymphoma 10.7 BCL6 CD5 MME
25 t-cell/histiocyte rich large b cell lymphoma 10.7 BCL6 IGH MME
26 cll/sll 10.7 CCND1 CD5 MME
27 lung lymphoma 10.7 BCL6 BIRC3 CD5 MALT1
28 mature b-cell neoplasm 10.6 BCL6 CD40 MME
29 angioimmunoblastic t-cell lymphoma 10.6 BCL6 CXCL13 MME
30 lymphoblastic lymphoma 10.6 BCL6 CD5 MME
31 composite lymphoma 10.6 BCL6 CD5
32 neurosyphilis 10.5 CXCL13 CXCR5
33 bladder lymphoma 10.5 CD5 MME
34 leukemia, acute lymphoblastic 3 10.5 CXCR5 FOXP1 IGH MME
35 hematologic cancer 10.4 BCL6 CCND1 CD5 MME
36 thyroiditis 10.3
37 intraocular lymphoma 10.3 BCL6 CXCR5
38 adenocarcinoma 10.2
39 helicobacter pylori infection 10.2
40 colon lymphoma 10.2 BCL6 CD5
41 hepatitis 10.1
42 gastritis 10.1
43 autoimmune disease 10.1
44 autoimmune disease 1 10.1
45 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
46 gastric cancer 10.1
47 mucositis 10.1
48 chlamydia 10.1
49 gastric adenocarcinoma 10.1
50 duodenitis 10.0

Graphical network of the top 20 diseases related to Lymphoma, Mucosa-Associated Lymphoid Type:



Diseases related to Lymphoma, Mucosa-Associated Lymphoid Type

Symptoms & Phenotypes for Lymphoma, Mucosa-Associated Lymphoid Type

Clinical features from OMIM:

137245

Human phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

59 32 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000505
2 abnormality of the thyroid gland 59 32 occasional (7.5%) Occasional (29-5%) HP:0000820
3 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
4 anemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001903
5 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
6 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
7 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
8 pulmonary infiltrates 59 32 hallmark (90%) Very frequent (99-80%) HP:0002113
9 recurrent respiratory infections 59 32 occasional (7.5%) Occasional (29-5%) HP:0002205
10 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191
11 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
12 mediastinal lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100721
13 hyperhidrosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000975
14 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
15 posterior uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012123
16 abnormality of the nasolacrimal system 59 Occasional (29-5%)
17 lymphadenopathy 59 Occasional (29-5%)
18 gastric lymphoma 32 HP:0045038
19 abnormal nasolacrimal system morphology 32 occasional (7.5%) HP:0000614

GenomeRNAi Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 BIRC3 CARD11 DUSP5 MALT1 BCL10 BIRC2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 BIRC3 CARD11 CCND1 CD40 DUSP5 MALT1

MGI Mouse Phenotypes related to Lymphoma, Mucosa-Associated Lymphoid Type:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 CXCR3 BCL6 CXCR5 BIRC2 DUSP5 HSPD1
2 hematopoietic system MP:0005397 10 BCL6 CXCR5 BIRC2 DUSP5 BIRC3 MALT1
3 immune system MP:0005387 9.83 CXCR5 BIRC2 DUSP5 BIRC3 MALT1 CARD11
4 normal MP:0002873 9.23 CXCR3 BCL6 CXCR5 BIRC2 BIRC3 CCND1

Drugs & Therapeutics for Lymphoma, Mucosa-Associated Lymphoid Type

Drugs for Lymphoma, Mucosa-Associated Lymphoid Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
6
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
7
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimalarials Phase 4,Phase 2,Phase 1
25
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
26
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
27
Pixantrone Approved, Investigational Phase 3 144510-96-3
28
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
29
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 32326 21704
30
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
31
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
32
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Ofloxacin Approved Phase 3 82419-36-1 4583
35
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
36
Idarubicin Approved Phase 3 58957-92-9 42890
37
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
38
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
40
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
41
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
42
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
44
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
45
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
46
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
47
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
48
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
49
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
50
Dexlansoprazole Approved, Investigational Phase 3,Phase 2 138530-94-6, 103577-45-3 9578005

Interventional clinical trials:

(show top 50) (show all 697)
# Name Status NCT ID Phase Drugs
1 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
4 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
7 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
10 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
14 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
16 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
17 Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00310167 Phase 3
18 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
19 A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
20 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
21 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed NCT00255190 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR
22 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
23 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
24 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
25 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
26 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
27 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
28 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
29 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
30 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
31 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
32 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
33 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
34 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
35 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
36 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
37 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
38 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
39 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
40 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
41 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
42 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
43 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
44 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
45 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
46 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
47 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
48 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
49 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
50 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Mucosa-Associated Lymphoid Type

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Lymphoma, Mucosa-Associated Lymphoid Type:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Lymphoma, Mucosa-Associated Lymphoid Type:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell, marginal zone

Genetic Tests for Lymphoma, Mucosa-Associated Lymphoid Type

Anatomical Context for Lymphoma, Mucosa-Associated Lymphoid Type

MalaCards organs/tissues related to Lymphoma, Mucosa-Associated Lymphoid Type:

41
B Cells, Bone, Bone Marrow, T Cells, Thyroid, Liver, Lung

Publications for Lymphoma, Mucosa-Associated Lymphoid Type

Articles related to Lymphoma, Mucosa-Associated Lymphoid Type:

(show top 50) (show all 630)
# Title Authors Year
1
Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy. ( 29582109 )
2018
2
Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary SjAPgren syndrome (pSS). ( 29424433 )
2018
3
Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. ( 28808514 )
2017
4
Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma. ( 28331132 )
2017
5
Primary pulmonary MALT lymphoma presenting as non-resolving pneumonia. ( 28871587 )
2017
6
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 28833354 )
2017
7
MALT lymphoma arising on a background of reactive pulmonary lymphoid hyperplasia in a patient with Systemic Lupus Erythematosus. ( 28945277 )
2017
8
A primary esophageal MALT lymphoma patient with<i>Helicobacter pylori</i>infection achieved complete remission after<i>H. pylori</i>eradication without anti-lymphoma treatment. ( 28053856 )
2017
9
MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis. ( 28031239 )
2017
10
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. ( 28695630 )
2017
11
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon: A Case Report and a Literature Review. ( 28469125 )
2017
12
Radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum: a case report. ( 28815477 )
2017
13
A MALT lymphoma prognostic index. ( 28720586 )
2017
14
A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma. ( 26966907 )
2016
15
Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma. ( 27435814 )
2016
16
Solitary pulmonary MALT lymphoma presenting crystal-storing histiocytosis. ( 27599420 )
2016
17
Triple synchronous gastric tumors: A rare combination diffuse adenocarcinoma, B-cell MALT lymphoma and large cell neuroendocrine carcinoma. ( 27986297 )
2016
18
Primary Endometrial Marginal Zone Lymphoma (MALT Lymphoma): A Unique Clinicopathologic Entity. ( 27340748 )
2016
19
MALT lymphoma: A paradigm of NF-I_B dysregulation. ( 27452667 )
2016
20
Differences in amino acid frequency in CagA and VacA sequences of<i>Helicobacter pylori</i>distinguish gastric cancer from gastric MALT lymphoma. ( 27833662 )
2016
21
Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. ( 25569716 )
2015
22
Images in clinical medicine. Bilateral lower palpebral MALT lymphoma. ( 25607429 )
2015
23
A 44-year old male with right-sided facial numbness. Dura-associated extranodal marginal zone B cell lymphoma (MALT lymphoma). ( 25521183 )
2015
24
Proximal weakness in a patient with MALT lymphoma: a case report and discussion of possible pathogenesis. ( 25763887 )
2015
25
The first case of human autochtonous subconjunctival dirofilariosis in Poland and MALT lymphoma as possible consequence of this parasitosis. ( 25589901 )
2015
26
A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. ( 25551313 )
2015
27
Epstein-barr virus-associated extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma) arising in the parotid gland of a child with ataxia telangiectasia. ( 25692616 )
2015
28
A case of MALT lymphoma of the colon, stomach, and small intestine. ( 25748153 )
2015
29
Pulmonary MALT lymphoma: A case report and review of the literature. ( 25452791 )
2015
30
Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma. ( 25801243 )
2015
31
Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature. ( 24646004 )
2015
32
Flow cytometry in the differential diagnostics of Hashimoto's thyroiditis and MALT lymphoma of the thyroid. ( 25754285 )
2015
33
Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up. ( 25579756 )
2015
34
A case of obstructive jaundice caused by MALT lymphoma of the common bile duct and the papilla of Vater. ( 25748157 )
2015
35
A Case of a Laryngeal MALT Lymphoma in a Patient with a History of Gastric MALT. ( 25664189 )
2015
36
Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa. ( 26425558 )
2015
37
Recurrence after Radiotherapy for Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma with Trisomy 18. ( 25876571 )
2015
38
Central retinal vein occlusion caused by hyperviscosity syndrome in a young patient with SjAPgren's syndrome and MALT lymphoma. ( 25711376 )
2015
39
Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients. ( 25077481 )
2014
40
Isolated gastric amyloidoma in the setting of marginal zone MALT lymphoma: case report and review of the literature. ( 24974561 )
2014
41
Subglotic malt-lymphoma of the larynx: an unusual presentation of chronic cough. ( 25280040 )
2014
42
A journey into insidious world of MALT lymphoma of the ileum: from the beginning to the end. ( 25436136 )
2014
43
Colonic mucosa-associated lymphoid tissue (MALT) lymphoma: an important differential diagnosis for a slow-growing colonic polyp. ( 25502272 )
2014
44
Extranodal marginal zone B-cell lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma) in ulcerative colitis. ( 25253369 )
2014
45
Spontaneous regression of primary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) colliding with invasive ductal carcinoma of the breast: a case report. ( 25400790 )
2014
46
Gastric MALT lymphoma - update on diagnosis and treatment. ( 25439072 )
2014
47
MALT lymphoma of the small bowel with protein-losing enteropathy. ( 24395281 )
2014
48
Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition. ( 25398916 )
2014
49
Uveal MALT lymphoma with extensive AL-type amyloid production mimicking uveal melanoma. ( 24853590 )
2014
50
Gastric diffuse large B-cell lymphoma cured with Helicobacter pylori eradication regardless of whether it contains features of MALT lymphoma. ( 24694478 )
2014

Variations for Lymphoma, Mucosa-Associated Lymphoid Type

Cosmic variations for Lymphoma, Mucosa-Associated Lymphoid Type:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM36072 NOTCH2 haematopoietic and lymphoid tissue,extranodal,lymphoid neoplasm,MALT lymphoma c.4912C>T p.H1638Y 1:119922726-119922726 12
2 COSM35925 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1004T>G p.L335* 6:137878449-137878449 10
3 COSM303672 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.559C>T p.Q187* 6:137875760-137875760 10
4 COSM303675 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1507C>T p.Q503* 6:137878952-137878952 10
5 COSM303674 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1282G>T p.E428* 6:137878727-137878727 10
6 COSM303671 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.733A>T p.R245* 6:137876094-137876094 10
7 COSM303679 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.581T>C p.I194T 6:137875782-137875782 10
8 COSM303677 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1367G>T p.G456V 6:137878812-137878812 10
9 COSM303694 TNFAIP3 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.1485T>A p.C495* 6:137878930-137878930 10
10 COSM85940 MYD88 haematopoietic and lymphoid tissue,ocular adnexa,lymphoid neoplasm,MALT lymphoma c.794T>C p.L265P 3:38141150-38141150 10

Copy number variations for Lymphoma, Mucosa-Associated Lymphoid Type from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 119732 18 16100000 76117153 Gain MALT1 Mucosa-associated lymphoid tissue lymphomas
2 206010 6 135101251 139048099 Loss TNFAIP3 Mucosa-associated lymphoid tissue lymphomas

Expression for Lymphoma, Mucosa-Associated Lymphoid Type

Search GEO for disease gene expression data for Lymphoma, Mucosa-Associated Lymphoid Type.

Pathways for Lymphoma, Mucosa-Associated Lymphoid Type

Pathways related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 BCL10 BCL6 BIRC2 BIRC3 CARD11 CCND1
2
Show member pathways
13.22 BCL6 BIRC2 BIRC3 CCND1 CD40 DUSP5
3
Show member pathways
12.53 BCL10 CARD11 CD40 MALT1 TRAF2
4
Show member pathways
12.35 BCL10 CARD11 CCND1 CD40 CXCL13 CXCR5
5
Show member pathways
12.33 BIRC2 BIRC3 CD40 TRAF2
6 12.31 BCL10 BCL6 CARD11 CXCR5 MALT1 TRAF2
7
Show member pathways
12.23 BCL10 CARD11 CD40 MALT1
8
Show member pathways
12.21 BCL10 BCL6 CARD11 MALT1
9 12.03 BCL10 BIRC2 BIRC3 MALT1 TRAF2
10
Show member pathways
11.83 CXCL13 CXCR3 CXCR5
11
Show member pathways
11.79 BCL10 CARD11 MALT1
12 11.79 BIRC2 BIRC3 TRAF2
13 11.73 BIRC2 BIRC3 CCND1 TRAF2
14
Show member pathways
11.65 BIRC2 CXCL13 TRAF2
15
Show member pathways
11.57 BIRC2 BIRC3 CD40 TRAF2
16
Show member pathways
11.5 BIRC2 BIRC3 CCND1
17 11.28 BCL6 CD40 CD5 CXCR5 MME
18 11.15 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
19 11.03 BIRC2 BIRC3 CD40 TRAF2
20 10.97 BCL10 BIRC2 MALT1

GO Terms for Lymphoma, Mucosa-Associated Lymphoid Type

Cellular components related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.62 CD40 CD5 CXCR3 CXCR5
2 membrane raft GO:0045121 9.55 BCL10 BIRC2 BIRC3 CARD11 TRAF2
3 T cell receptor complex GO:0042101 9.37 BCL10 CARD11
4 lipopolysaccharide receptor complex GO:0046696 9.26 BCL10 HSPD1
5 CD40 receptor complex GO:0035631 9.13 BIRC2 CD40 TRAF2
6 CBM complex GO:0032449 8.8 BCL10 CARD11 MALT1

Biological processes related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 BIRC2 BIRC3 CXCL13 CXCR3
2 regulation of cell proliferation GO:0042127 9.96 BCL6 BIRC2 CD40 CXCL13
3 regulation of immune response GO:0050776 9.95 BCL6 CARD11 CD40 MADCAM1
4 response to lipopolysaccharide GO:0032496 9.92 CD40 CXCL13 FOXP1 S100A8
5 chemotaxis GO:0006935 9.88 CXCL13 CXCR3 CXCR5 S100A8
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.87 BCL10 CARD11 MALT1
7 response to ethanol GO:0045471 9.87 BIRC2 CCND1 S100A8
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 BIRC2 BIRC3 CD40 TRAF2
9 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.84 HSPD1 S100A8 TRAF2
10 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL13 CXCR3 CXCR5
11 positive regulation of protein ubiquitination GO:0031398 9.8 BCL10 BIRC3 MALT1
12 regulation of inflammatory response GO:0050727 9.77 BCL6 BIRC2 BIRC3 FOXP1 S100A8
13 protein heterooligomerization GO:0051291 9.76 BCL10 BIRC2 BIRC3 TRAF2
14 positive regulation of B cell proliferation GO:0030890 9.73 BCL6 CARD11 CD40
15 B cell activation GO:0042113 9.71 CD40 CXCR5 HSPD1 MALT1
16 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.69 BIRC2 BIRC3
17 activation of NF-kappaB-inducing kinase activity GO:0007250 9.69 MALT1 TRAF2
18 regulation of innate immune response GO:0045088 9.68 BIRC2 BIRC3
19 positive regulation of interleukin-2 production GO:0032743 9.67 MALT1 TRAF2
20 response to molecule of bacterial origin GO:0002237 9.67 BCL10 MALT1
21 B cell proliferation GO:0042100 9.67 CARD11 CD40 HSPD1
22 negative regulation of necroptotic process GO:0060546 9.66 BIRC2 BIRC3
23 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 9.65 BIRC2 BIRC3
24 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.65 BIRC2 BIRC3 TRAF2
25 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.65 BCL10 BIRC2 BIRC3 CARD11 TRAF2
26 positive regulation of T cell cytokine production GO:0002726 9.64 MALT1 TRAF2
27 negative regulation of B cell apoptotic process GO:0002903 9.64 BCL6 FOXP1
28 germinal center formation GO:0002467 9.63 BCL6 CXCL13
29 chronic inflammatory response GO:0002544 9.63 CXCL13 S100A8
30 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 BCL10 CARD11 CD40 MALT1 S100A8 TRAF2
31 positive regulation of T cell activation GO:0050870 9.62 BCL10 CARD11 HSPD1 MALT1
32 response to fungus GO:0009620 9.61 BCL10 MALT1
33 regulation of necroptotic process GO:0060544 9.61 BIRC2 BIRC3 TRAF2
34 regulation of T cell receptor signaling pathway GO:0050856 9.59 BCL10 MALT1
35 regulation of toll-like receptor signaling pathway GO:0034121 9.58 BIRC2 BIRC3
36 regulation of immunoglobulin secretion GO:0051023 9.57 CD40 TRAF2
37 regulation of apoptotic process GO:0042981 9.56 BCL10 BCL6 BIRC2 BIRC3 CARD11 CD40
38 regulation of cysteine-type endopeptidase activity GO:2000116 9.54 BIRC2 BIRC3
39 regulation of nucleotide-binding oligomerization domain containing signaling pathway GO:0070424 9.52 BIRC2 BIRC3
40 regulation of RIG-I signaling pathway GO:0039535 9.51 BIRC2 BIRC3
41 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.17 BCL10 BIRC2 BIRC3 CARD11 CD40 MALT1
42 protein ubiquitination GO:0016567 10.08 BCL10 BIRC2 BIRC3 MALT1 TRAF2
43 negative regulation of apoptotic process GO:0043066 10.08 BCL6 BIRC2 BIRC3 HSPD1 MALT1
44 apoptotic process GO:0006915 10.08 BCL10 BIRC2 BIRC3 CXCR3 S100A8 TRAF2
45 inflammatory response GO:0006954 10 BCL6 CD40 CXCL13 CXCR3 S100A8

Molecular functions related to Lymphoma, Mucosa-Associated Lymphoid Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.62 BCL10 CD40 HSPD1 TRAF2
2 C-X-C chemokine receptor activity GO:0016494 9.26 CXCR3 CXCR5
3 kinase activator activity GO:0019209 9.16 BCL10 MALT1
4 protein self-association GO:0043621 9.13 BCL10 FOXP1 MALT1
5 enzyme binding GO:0019899 9.02 BCL10 CCND1 CD40 HSPD1 TRAF2

Sources for Lymphoma, Mucosa-Associated Lymphoid Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....